MEMBERSHIP INTEREST PURCHASE AGREEMENT by and among Pasithea Therapeutics Corp., Alpha-5 integrin, LLC, The Persons listed on Schedule 1.1, and Paul B. Manning, as the Representative Dated June 21, 2022Membership Interest Purchase Agreement • June 22nd, 2022 • Pasithea Therapeutics Corp. • Pharmaceutical preparations • Delaware
This Membership Interest Purchase Agreement (this “Agreement”) is entered into on June 21, 2022 by and among Pasithea Therapeutics Corp., a Delaware Corporation (“Buyer”), Alpha-5 integrin, LLC, a Delaware limited liability company (the “Company”), the Persons listed on Schedule 1.1 (each individually a “Seller” and collectively, “Sellers”), and Paul B. Manning, not individually but in his capacity as the representative of Sellers (the “Representative”). Buyer, the Company, Sellers and the Representative are referred to collectively herein as the “Parties” and individually as a “Party.” Unless otherwise specifically stated, each Seller shall be severally and not jointly liable with each other Seller for the liabilities and obligations of each and all Sellers hereunder.
